Virbac to Release Financial Results, Hold Conference Call On May 2.Business Editors FORT WORTH, Texas--(BUSINESS WIRE)--April 25, 2002 Virbac Corporation (NASDAQ NM: VBAC VBAC - Vaginal Birth After Cesarean (Section) VBAC - Vector Bundles on Algebraic Curves VBAC - venous blood alcohol concentration VBAC - Veterinary Biologic Advisory Committee (USDA) VBAC - Victorian Branch Abseiling Council (Australia) VBAC - View-Based Access Control VBAC - vinylbenzyl acetate VBAC - Virbac Corporation (NASDAQ stock symbol) VBAC - Virginia Beach Animal Control), a leading companion animal health company, will release its first quarter financial results for the period ended March 31, 2002 on Thursday, May 2, 2002. A conference call will also be held on May 2 at 11:00 A.M. EST to discuss the company's quarterly and twelve-month results. Those who wish to participate in the conference call may telephone (888) 335-6674 approximately 15 minutes before the 11:00 A.M. starting time. A digital replay will be available by telephone for 30 days at (877) 519-4471 toll free in the United States or (973) 341-3080 for international callers, PIN # 3246198. Virbac Corporation, located in Fort Worth, Texas, is a leading companion animal health company focusing on the pharmaceuticals, dermatological and oral hygiene markets for pets and companion animals, and provides a broad array of healthcare products to its customers under the C.E.T.(R) Home Dental Care, Allerderm(R) Dermatological Products, St. JON(R), Zema(R), Mardel(R), Pet-Tabs(R) and Francodex(R) brand names. For more information on Virbac, please visit www.virbac.com. This press release contains forward-looking information made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be affected by certain risks and uncertainties described in the company's filings with the Securities and Exchange Commission. The company's actual results could differ materially from such forward-looking statements. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion